Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gold-Based Drug Shows Promise Against Bone Cancer

March 26, 2014 12:35 pm | News | Comments

A gold-based drug currently used in human and veterinary medicine to manage certain immune diseases may prove useful in combating osteosarcoma, researchers report. Read more...                      

TOPICS:

Immunotherapy Data Heralds New Era of Lung Cancer Treatment

March 26, 2014 12:26 pm | News | Comments

For decades, scientists and doctors thought immunotherapy– treatments that harness the immune system to fight a disease– was of marginal benefit in lung cancer. Now, a new class of drugs known as “immunocheckpoint regulators” have shown huge potential in treating the disease. Read more...

TOPICS:

AM-Pharma Announces Phase 1 AKI Drug Data

March 26, 2014 12:15 pm | News | Comments

AM-Pharma B.V. announced the results of its Phase 1 trial with of recAP (recombinant human Alkaline Phosphatase), showing that both single and multiple ascending doses are safe and well tolerated. Read more...          

TOPICS:
Advertisement

FDA Approves Actavis-Valeant Bacterial Gel

March 26, 2014 12:03 pm | News | Comments

Actavis and Valeant Pharmaceuticals announced that the FDA has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Read more...             

TOPICS:

Inovio Snags Best Therapeutic Award at World Vaccine Congress

March 26, 2014 10:05 am | News | Comments

Inovio Pharmaceuticals Inc. announced that it was recognized with three industry awards at the World Vaccine Congress, being held this week in Washington, D.C. Read more...                       

TOPICS:

AstraZeneca Buys Out Sumitomo’s Stake in Japan Subsidiary

March 26, 2014 9:55 am | News | Comments

AstraZeneca announced it has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K. The purchase was valued at approximately 10 billion Japanese yen. Read more...               

TOPICS:

Astellas Wins Prostate Cancer Approval for Xtandi in Japan

March 25, 2014 2:15 pm | News | Comments

Astellas Pharma announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, Xtandi capsules 40mg (enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Read more...

TOPICS:

Spark, Genable Technologies Collaboration on Rare Gene Therapy

March 25, 2014 2:04 pm | News | Comments

Spark Therapeutics and Genable Technologies announced that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038. Read more...    

TOPICS:
Advertisement

New Cancer Drug Manipulates Signaling, Energy Systems

March 25, 2014 1:59 pm | News | Comments

Researchers have developed a new drug that can manipulate the body’s natural signaling and energy systems, allowing the body to attack and shut down cancerous cells. Read more...                     

TOPICS:

Study Questions First-Line Treatment for Advanced Sarcoma

March 25, 2014 1:50 pm | News | Comments

A new study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor. Read more...                 

TOPICS:

Marijuana Pill, Spray May Ease Some MS Symptoms

March 25, 2014 1:37 pm | News | Comments

A new guideline from the American Academy of Neurology states that oral cannabis, or medical marijuana pills, and oral medical marijuana spray may ease the symptoms of multiple sclerosis (MS). Read more...          

TOPICS:

Pfizer's Xalkori Extends Lung Cancer Survival

March 25, 2014 1:28 pm | News | Comments

Pfizer announced that PROFILE 1014, a Phase 3 study of anaplastic lymphoma kinase (ALK) inhibitor Xalkori (crizotinib), met its primary objective of significantly prolonging progression-free survival (PFS) when compared to standard platinum-based chemotherapy regimens. Read more...

TOPICS:

New Research Seeks DNA Vaccine Against HIV, Hep C

March 25, 2014 11:29 am | News | Comments

Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with researchers applying for a patent based on groundbreaking new research. Read more...         

TOPICS:

Ferrer, Medimetriks in Licensing Agreement for Impetigo Drug

March 25, 2014 11:20 am | News | Comments

Medimetriks Pharmaceuticals Inc. announced a licensing agreement with Ferrer for the commercialization rights to Ozenoxacin 1% Cream in the United States. Ozenoxacin is a novel, bactericidal non-fluorinated quinolone in development as a topical treatment for impetigo. Read more...

TOPICS:

Takeda Hypertension Drug Gets OK in Japan

March 25, 2014 11:05 am | News | Comments

Takeda announced that the Japanese Ministry of Health, Labor and Welfare has approved the New Drug Application of Zacras tablets for treatment of hypertension. Read more...                       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading